Madison, CT, United States of America

Stėphane DeLombaert

This inventor holds 1 USPTO granted patent. Top assignee: Neurogen Corporation. Active years: 2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stėphane DeLombaert. Retrieved from https://idiyas.com/inventor/stėphane-delombaert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Stėphane DeLombaert: Innovator in Arylpyrazine Compounds

Introduction

Stėphane DeLombaert is a notable inventor based in Madison, Connecticut. He has made significant contributions to the field of medicinal chemistry, particularly through his work on arylpyrazine compounds. His innovative approach has the potential to impact the treatment of various disorders associated with CRF receptors.

Latest Patents

Stėphane holds a patent for "Substituted arylpyrazines." This patent describes arylpyrazine compounds that exhibit high affinity and selectivity for CRF receptors, including those in humans. The invention outlines methods for treating disorders and diseases linked to CRF receptors, especially CNS-related disorders, affective disorders, and both acute and chronic neurological conditions.

Career Highlights

Stėphane is currently employed at Neurogen Corporation, where he continues to advance his research and development efforts. His work at Neurogen has positioned him as a key player in the field of neuropharmacology, focusing on innovative solutions for complex neurological issues.

Collaborations

Stėphane collaborates with talented colleagues, including Taeyoung Yoon and Ping Ge. Their combined expertise fosters a dynamic research environment that enhances the potential for groundbreaking discoveries.

Conclusion

Stėphane DeLombaert's contributions to the field of medicinal chemistry, particularly through his patent on arylpyrazine compounds, highlight his role as an innovator in the treatment of CNS-related disorders. His work at Neurogen Corporation and collaborations with esteemed colleagues further underscore his commitment to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…